Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
12 Novembro 2021 - 02:18PM
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
biopharmaceutical company focused on enabling normal lives for
people with autoimmune diseases, today announced that Pete
Salzmann, M.D., Chief Executive Officer, will provide a corporate
overview at the Stifel 2021 Virtual Healthcare Conference, taking
place November 15-17, 2021.
Stifel 2021 Virtual Healthcare Conference
Presentation
Date: |
Wednesday,
November 17th, 2021 |
Time: |
2:00pm Eastern Time |
Webcast: |
The presentation will be available via webcast and can be
accessed at the Investor Relations section of the Company’s
website, located at www.immunovant.com |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company
focused on enabling normal lives for people with autoimmune
diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel,
fully human anti-FcRn monoclonal antibody, as a subcutaneous
injection for the treatment of autoimmune diseases mediated by
pathogenic IgG antibodies.
Contact:
Tom Dorney, MS, MBADirector, Investor Relations &
StrategyImmunovant, Inc.info@immunovant.com
Immunovant (NASDAQ:IMVT)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Immunovant (NASDAQ:IMVT)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024